2022/02/04 update
New Light on Fertility Treatments;
9 Drugs for Fertility Treatment to Be Listed in April
In line with the introducing health coverage for fertility treatments from next April, the Central Social Insurance Medical Council (Chuikyo) approved the NHI price list of nine drugs for fertility treatments. Listing is scheduled for April 1.
Health coverage for infertility treatment is one of the measures compiled by former Prime Minister Yoshihide Suga to improve Japan’s low birthrate.
This is just the first step to address the falling birthrate, but is definitely one giant leap for us in the future workforce.
Contact us if you have any questions about pricing and market access in Japan.
Newly Listed drugs (on April, 2022)
| Brand name | Unit specification | Applicant | Active ingredient | Approval category | NHI price (yen) | Pricing method | Adjustment premiums etc. | Indication |
| Viagra Tablet Viagra Sheet |
25 mg/tablet 50 mg/tablet 25 mg/sheet 50 mg/sheet |
Viatris | sildenafil citrate | New active ingredient | 959.60 1,380.00 991.60 1,424.10 |
Cost calculation method | – Utility premium (II) A=5% | Erectile dysfunction (NME) |
| Cialis Tablet | 5 mg/tablet 10 mg/tablet 20 mg/tablet |
Nippon Shinyaku | tadalafil | New active ingredient | 1,343.80 1,454.60 1,529.90 |
Cost calculation method | – Utility premium (II) A=5% | Erectile dysfunction (NME) |
| Rekovelle Pen for SC Injection | 12 µg/0.36 ml/syringe 36 µg/1.08 ml/syringe 72 µg/2.16 ml/syringe |
Ferring Pharma | follitropin delta (recombinant) | New active ingredient | 15,103 36,394 63,390 |
Price comparator method (I) | Controlled ovarian stimulation in women undergoing assisted reproductive technology (NME) | |
| Ganirest Subcutaneous | 0.25 mg/0.5 ml/syringe | Organon | ganirelix acerate | New active ingredient | 9,085 | Price comparator method (I) | – Utility premium (II) A=5%
-New drug development premium |
Prevention of premature ovulation in women undergoing controlled ovarian simulation (NME) |
| Cetrotide for Injection | 0.25 mg/vial | Nippon Kayaku | cetrorelix acetate | New active ingredient | 9,241 | Price comparator method (I) | -Utility premium (II) A=5%
-New drug development premium |
Prevention of premature ovulation in women undergoing controlled ovarian simulation (NME) |
| Luteum Vaginal Suppositories | 400 mg/suppository | ASKA | progesterone | New route of administration | 553.10 | Price comparator method (I) | – Utility premium (II) A=5%
-New drug development premium |
Progesterone replacement therapy in women undergoing assisted reproductive technology |
| Ustogestan Vaginal Capsule | 200 mg/capsule
|
Fuji Pharma | progesterone | New route of administration | 368.80 | Price comparator method (I) | – Utility premium (II) A=5%
-New drug development premium |
Progesterone replacement therapy in women undergoing assisted reproductive technology
|
| Lutinus Vaginal Tablets | 100 mg/tablet | Ferring | progesterone | New route of administration | 368.80 | Price comparator method (I) | – Utility premium (II) A=5%
-New drug development premium |
Progesterone replacement therapy in women undergoing assisted reproductive technology
|
| OneCrinone Vaginal Gel | 90 mg/applicator | Merck Biopharma | progesterone | New route of administration | 4,106.40 | Price comparator method (I) | – Utility premium (II) A=5%
-New drug development premium |
Progesterone replacement therapy in women undergoing assisted reproductive technology
|
